Catalyst

Slingshot members are tracking this event:

Phase 2 Data of FG3019 Supports Potential for Treatment of Idiopathic Pulmonary Fibrosis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
FGEN

100%

Additional Information

Clinical Data FibroGen announced data from its Phase 2 study through the European Respiratory Journal on FG-3019 monoclonal antibody on treatment of idiopathic pulmonary fibrosis (IPF).  The study was designed to measure safety and efficacy and found that a "majority of subjects in the study (65%) exhibited an increase in fibrosis, 35% exhibited stable or improved fibrosis at week 48" and "27.0% experienced a total of 38 treatment-emergent serious adverse events (SAEs) during the trial."  FibroGen is encouraged by the data and is conducting a Phase 2 placebo controlled study.
http://investor.fibr...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fg-3019, Phase 2 Data, Idiopathic Pulmonary Fibrosis, Monoclonal Antibody